Our Journey

2025

Focus on commercialization and strategic partnership collaborations.

Cellevate, Fraunhofer IBMT and OLS consortium awarded EUR 1 million Eurostar grant for large scale production of induced pluripotent stem cells.

A benchmarking study comparing lentiviral vector production using Cellevat3d® nanofiber microcarriers with industry standard bead-based microcarriers demonstrated a significant 5-fold increase in functional lentiviral vector titers using Cellevat3d® nanofiber microcarriers.

A benchmarking study conducted by Intravacc (CDMO, NL) demonstrated more than a 10-fold increase in viral vaccine production titers using the novel Cellevat3d® nanofiber microcarriers compared to industry standard microcarriers.

Global launch of Cellevat3d® VAX nanofiber microcarriers in viral vaccine production at World Vaccine Congress Europe, Amsterdam, 13-16 October 2025.

ISO 9001 accreditation and GMP production.

2024

Launch and sales start of Cellevat3d® nanofiber-based cell culture product for viral vector production: November 4-6, BIO-Europe 2024, Stockholm, Sweden.

Cellevate establishes sales- and support core team in the USA to launch and commercialize the new category nanofiber cell culture systems.

Cellevate reaches commercial readiness and successfully closes in Q3 the 2nd seed financing round of 3.2 MEUR to support growth and commercialization, with continued support from the strong investor syndicate: Industrifonden, EIC Fund/EIB, Onsight Ventures and existing shareholders.

IP secured in gene therapy and stem cell therapy, production scale up, product validations and evaluations program with leading organizations in gene therapy, QMS/ISO 9001 and production according to GMP ongoing implementation to be finalized in 2025.

Dr. Uwe Gottschalk, world leading bioprocessing leader, appointed as Chairman of Cellevate Board of Directors.

Dr. Bettina Berendsen, top bioprocessing commercial executive, appointed as Board Observer and strategic commercial advisor.

Dr. Christel Fenge, product development and marketing executive strategic expert joins strategic advisory board.

2023

Closing of investment round of 3.6 MEUR for Cellevate scale-up and commercialization of Cellevat3d® nanotechnology in upstream bioprocessing: organization, QMS, ISO 9001, production, development, IP, sales and marketing.

2022

New strategy: Cellevat3d® nanofiber-based upstream bioprocessing solutions.

New CEO, Management Team and Scientific Advisory Board.

Awarded 2.48 MEUR EIC Accelerator grant and 3 MEUR EIC Fund equity investment for commercialization of Cellevat3d® microcarriers.

2017

First Cellevat3d® nanotechnology-based products are customized and sold as R&D Customized Solutions for cell co-culture research applications in neurology, immunology and cancer.

2014

Cellevate is founded as a spinout from NanoLund and Prof. Lars Montelius group.

Let’s talk

Contact us through the form below to book a meeting, or ask us questions.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.